1-10 of 10
Richard Julian Jones
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Junling Zhuang, Fazal Shirazi, Ram Kumar Singh, Isere Kuiatse, Hua Wang, Hans C. Lee, Zuzana Berkova, Allison Berger, Marc Hyer, Nibedita Chattopadhyay, Sakeena Syed, Judy Qiuju Shi, Jie Yu, Vaishali Shinde, Stephen Tirrell, Richard Julian Jones, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski
Journal: Blood
Blood (2019) 133 (14): 1572–1584.
https://doi.org/10.1182/blood-2018-06-859686
Published: 2019
Includes: Supplemental data
Journal Articles

The Anti-Tumor Effect of the Ubiquitin-Activating Enzyme (UAE) Inhibitor TAK-243 on Pre-Clinical Models of Multiple Myeloma

Junling Zhuang, MD PhD, Hans Lee, MD, Isere Kuiatse, PhD, Hua Wang, PhD, Fazal Shirazi, PhD, Allison Berger, PhD, Marc Hyer, PhD, Nibedita Chattopadhyay, PhD, Sakeena Syed, Judy Qiuju Shi, Jie Yu, M.S., Vaishali Shinde, Anna Kreshock, Stephen Tirrell, PhD, Saurabh Menon, PhD, Richard Julian Jones, PhD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3296.
https://doi.org/10.1182/blood.V128.22.3296.3296
Published: 2016
Journal Articles

RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma

Hans Lee, MD, Hua Wang, PhD, Heather Lin, M.S., Veera Baladandayuthapani, PhD, Jin He, Richard Julian Jones, PhD, Isere Kuiatse, PhD, Dongmin Gu, MD, PhD, Zhiqiang Wang, PhD, Sean O'Brien, PhD, Jonathan J Keats, PhD, Jing Yang, PhD, Richard Eric Davis, MD, Robert Z. Orlowski, PhD, MD
Journal: Blood
Blood (2015) 126 (23): 3010.
https://doi.org/10.1182/blood.V126.23.3010.3010
Published: 2015
Journal Articles

CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models

Hans C. Lee, MD, Hua Wang, Ph.D., Bing-Zong Li, M.D., Ph.D., Zhiqiang Wang, Ph.D., Richard Julian Jones, Ph.D., Dongmin Gu, M.D., Ph.D., Sean O'Brien, Ph.D., Richard E. Davis, M.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 4438.
https://doi.org/10.1182/blood.V122.21.4438.4438
Published: 2013
Journal Articles

Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications

Richard Julian Jones, Ph.D., Shannon C. Kenney, MD, Christopher Dawson, PhD, Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 3499.
https://doi.org/10.1182/blood.V122.21.3499.3499
Published: 2013
Journal Articles

Intravenous Immunoglobulin G (IVIg) Suppresses HSP70-1 and Has Potential Therapeutic Effects Against Multiple Myeloma and Lymphoma

Richard Julian Jones, Ph.D., Richard E. Davis, M.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 3845.
https://doi.org/10.1182/blood.V122.21.3845.3845
Published: 2013
Journal Articles

Inhibition of the HDM-2 E3 Ligase Induces Types I and II Cell Death in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically in Both with ABT-737.

Dongmin Gu, Ph.D., Richard Julian Jones, Ph.D., Hua Wang, Ph.D., Lance Leopold, M.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2012) 120 (21): 2940.
https://doi.org/10.1182/blood.V120.21.2940.2940
Published: 2012
Journal Articles

Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma

Deborah J. Kuhn, Ph.D., Hua Wang, Ph.D., Richard Julian Jones, PhD, Chad C. Bjorklund, Ph.D., Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 925.
https://doi.org/10.1182/blood.V118.21.925.925
Published: 2011
Journal Articles

Drug Resistance to the HDM-2 Inhibitors MI-63 and Nutlin Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

Richard Julian Jones, PhD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2726.
https://doi.org/10.1182/blood.V118.21.2726.2726
Published: 2011
Journal Articles

Inhibition of the Human Double Minute (HDM)-2 E3 Ubiquitin Ligase Activates Different Programmed Cell Death (PCD) Pathways in Models of Non-Hodgkin Lymphoma (NHL) with Wild Type (wt) and Mutant (mut) p53

Richard Julian Jones, PhD, Janine Arts, PhD, Robert Z Orlowski, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3618.
https://doi.org/10.1182/blood.V112.11.3618.3618
Published: 2008